Zepbound ® Dual Action:

Reduce Sleep Apnea Severity & Achieve Lasting Weight Loss

In December 2024, the FDA approved Zepbound ® (tirzepatide) as the first pharmaceutical treatment for adults with moderate-to-severe obstructive sleep apnea (OSA) and elevated weight.
Unlike mechanical treatments like CPAP or Inspire, Zepbound is a once-weekly injectable GLP-1 and GIP receptor agonist that addresses the underlying metabolic causes of OSA by promoting significant weight loss.
Clinical trials demonstrated that Zepbound can reduce breathing interruptions by an average of 25 to 30 events per hour, with nearly half of the participants achieving complete sleep apnea remission after one year of treatment.